ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. - Wikidata - awgldk - TriplyDB

ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.

ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.

http://www.wikidata.org/entity/Q37297173

about

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)Targeting molecular resistance in castration-resistant prostate cancer The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.Clinical significance of ABCB1 genotyping in oncology.Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer.Genetic variation: effect on prostate cancer.Impact of ABCB1 allelic variants on QTc interval prolongation.The functional influences of common ABCB1 genetic variants on the inhibition of P-glycoprotein by Antrodia cinnamomea extracts Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.Assessment of chemotherapy-induced peripheral neuropathy using the LDIFLARE technique: a novel technique to detect neural small fiber dysfunction Informative gene network for chemotherapy-induced peripheral neuropathy Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis.Pharmacogenetic pathway analysis of docetaxel elimination.Label-free isolation of a prostate cancer cell among blood cells and the single-cell measurement of drug accumulation using an integrated microfluidic chip.A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.Uptake carriers and oncology drug safety.Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment.Overcoming docetaxel resistance in prostate cancer: a perspective review.Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review.A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.New Oral Formulation and in Vitro Evaluation of Docetaxel-Loaded Nanomicelles.Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.Castration-resistant prostate cancer: targeted therapies and individualized treatment Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.

P2860

Q26774221-A3CBBAEE-46D4-4F6E-BE49-56F58E0F4FCE Q26795445-1DB8CF89-FD11-413B-A69F-FD2400CD8884 Q27025062-F0DA5517-38BA-4C61-AC2A-242689EE66BB Q30375556-D9DA27FF-1529-4465-9F46-8DD15060C004 Q33704464-8082039B-29E8-45C8-B74C-EAE5F9C3DEFD Q33951034-8E8CB40C-85FE-403C-A9E0-87F1817487D0 Q34036032-D632EB64-52C6-4F30-B8E1-497667D91096 Q34187283-F4D8B407-2D68-48E9-B0A9-ED511D406F53 Q34663656-3D6E46C0-B39D-4A04-BA46-647F8AEDD273 Q34781769-6791846B-30DC-4799-82EE-B97FE0D1BCD4 Q35107752-60C1DE3C-7AC2-4355-903F-10E4CBC00365 Q35674153-EDE5521F-4EFE-40C7-B30F-FF83D11ADC8D Q35722135-7468CABD-FFE9-4D7D-8EA8-035B23EFAFE1 Q35945680-8183BBD7-5D31-496B-B031-DD0A4EECC575 Q36043023-A467E374-EDE5-4AE3-AB9F-CD8B8A2958CD Q36182023-A3A3607D-8BBA-410C-BF3F-5531AF425388 Q36277902-A75112A4-456E-4985-A728-F823F4272AA0 Q36326889-9AB15CC1-1C41-4084-B6CB-23DE99C3C684 Q36988072-761A964A-6AA6-4E27-8DA6-6EE8820C14D9 Q37055326-6B833AB1-50C3-4F15-AB81-9A623D18A7EB Q37253554-06911959-7F9B-4FA8-8271-CFAEBF939F57 Q37659699-F4730A0C-781F-4A03-ABD9-92D0D8D63D08 Q37662576-17377974-4FB4-4CD3-8DBD-0AA47D03C156 Q37663396-3AC45EB9-CB08-44D7-8CD2-F29D5C37161F Q37684533-EFA4D6C9-8CFE-42FE-88C6-CB76CE1595AF Q37735146-4A9BA531-08CB-4CF6-AD75-4555FA3E6328 Q37946959-82563B25-EDFD-4AA9-8333-8ED4FDBD5E9D Q38057235-18254BC8-318D-42A0-953B-E058C8CE3095 Q38065218-A2733FFE-342C-43B6-B173-F61BECDA0D55 Q38069776-0FBF5620-3770-4211-AC79-E897B33A81D3 Q38207448-8C112045-FD0B-45AD-8FC5-C7AA624A15FD Q38347610-2EEA72AF-550D-41FF-869B-ECFA8A50255B Q38414396-0E70E9D9-D1C2-44E7-89F4-FC7145157703 Q38551666-988A14B2-3B97-406A-82A8-D2BB209A57A5 Q38744407-01C0E2FD-F7E0-4A2B-A2FE-24CD556D3DA4 Q38933314-F00C2B5F-B56D-44F0-B18D-B890D23767FA Q39511732-B8CC5210-F99A-455A-B6CD-0B398559FD27 Q39702921-A1DCCC22-E461-4B59-B966-1DE25B75CB4B Q39796533-D45828F8-8325-4600-AA99-BE63FECE7087 Q40715631-55AD5940-34D4-4A45-AA5D-6A6B7BAA417A

P2860

ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.

http://www.wikidata.org/entity/Q37297173

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

ABCB1 genetic variation influe ...... cancer treated with docetaxel.

@en

ABCB1 genetic variation influe ...... cancer treated with docetaxel.

@nl

type

label

ABCB1 genetic variation influe ...... cancer treated with docetaxel.

@en

ABCB1 genetic variation influe ...... cancer treated with docetaxel.

@nl

prefLabel

ABCB1 genetic variation influe ...... cancer treated with docetaxel.

@en

ABCB1 genetic variation influe ...... cancer treated with docetaxel.

@nl

P1433

Q37297173-EAA9AC7B-4158-46FB-B81A-F86343C69D7B

P1476

Q37297173-AEEFBD04-BE0D-4C44-A031-31DF22081684

P2093

Q37297173-04F22131-4D1B-4C5A-97CF-402B3EBB7993

Q37297173-22CC7202-A931-4FA5-8810-C13B08F11F53

Q37297173-67418D7C-331A-4153-A59E-60151D05BE6D

Q37297173-6FD0AB14-F939-4BAF-B27B-6AAA415C7DCD

Q37297173-8E87B0B7-B426-48BE-8657-2245CF091FEA

Q37297173-96E3E6E0-AF6F-46E7-8AB1-240ACFEB647B

Q37297173-B23113D5-E2AE-457B-8288-C4731D06B305

Q37297173-E53764B0-AF52-4825-8403-F9A1058D5964

P2860

Q37297173-259B74C0-36A7-4A6C-98E1-CFD25C34CA98

Q37297173-29763A71-8362-4881-93AA-A57F1A4226CA

Q37297173-32715223-C57E-4D79-B8E6-8DD3B4E26079

Q37297173-3A1D3114-81A7-441E-BE90-7361DE7FB1FF

Q37297173-3B3A708A-2132-43AA-A1F9-01E6C04923F4

Q37297173-4425C452-F68B-4A73-8DBA-691CA2721D3B

Q37297173-45653254-219C-4F26-9570-7FCAFC156859

Q37297173-4927CD5B-E49B-429A-B709-58D58EC81201

Q37297173-496302C8-FE1C-4C19-9E12-C9D636D9BF08

Q37297173-5F521F21-BAE7-49A4-A6BF-7D16EB8944B5

P304

Q37297173-8152B653-F1C2-4FCA-9381-482CE8E9419D

P31

Q37297173-088A9B9C-4C0B-47EB-B866-BF811A7841F1

P356

Q37297173-E4A98DFF-71E0-4CC5-B08F-75E7CB71BEA5

P407

Q37297173-508D591E-DF20-4F10-BBD4-49BF26B981B9

P433

Q37297173-12D462BC-1D81-4025-B57A-5ADF4C539317

P478

Q37297173-24005360-F20D-48AE-A561-9FBDC36BE99A

P50

Q37297173-FBEC41BC-F1F3-432A-822A-38F0BB333AFF

P577

Q37297173-B0481698-B198-434C-BD79-65EC7FD8211C

P698

Q37297173-B5F6E190-DB5F-4764-8D1B-9C8BA9A2D789

P921

Q37297173-9A2E1DC6-B57D-448A-9813-946A903B8A1C

P932

Q37297173-A0D271C5-61E9-4894-9026-66F9FB9592FE

P356

1078-0432.CCR-07-4230

P1433

Clinical Cancer Research

P1476

ABCB1 genetic variation influe ...... cancer treated with docetaxel.

@en

P2093

Caitlin E Baum

http://www.w3.org/2001/XMLSchema#string

Douglas K Price

http://www.w3.org/2001/XMLSchema#string

Jeanny Aragon-Ching

http://www.w3.org/2001/XMLSchema#string

John Deeken

http://www.w3.org/2001/XMLSchema#string

Seth M Steinberg

http://www.w3.org/2001/XMLSchema#string

Tristan M Sissung

http://www.w3.org/2001/XMLSchema#string

William D Figg

http://www.w3.org/2001/XMLSchema#string

William Dahut

http://www.w3.org/2001/XMLSchema#string

P2860

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer

mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.

P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells

Multidrug resistance in cancer: role of ATP-dependent transporters

Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

A "silent" polymorphism in the MDR1 gene changes substrate specificity

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

Evaluation of survival data and two new rank order statistics arising in its consideration.

P304

4543-4549

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-07-4230

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Alex Sparreboom

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18628469

http://www.w3.org/2001/XMLSchema#string

P921

P932

2723795

http://www.w3.org/2001/XMLSchema#string